|
WO2021053194A1
|
|
Kv1.3 blockers
|
|
WO2021037502A1
|
|
Adapter for a fluid transfer device
|
|
WO2021009266A1
|
|
Pharmaceutical composition for subcutaneous administration
|
|
WO2020249782A1
|
|
Pharmaceutical parenteral composition of dual glp1/2 agonist
|
|
WO2020020904A1
|
|
Therapeutic uses of glp-2 agonists
|
|
WO2019166411A1
|
|
Compstatin analogues and their medical uses
|
|
US2019330295A1
|
|
Glucagon-like-peptide-2 (glp-2) analogues
|
|
EP3628683A1
|
|
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
|
EP3628682A1
|
|
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
|
WO2018229252A1
|
|
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
|
CN110709096A
|
|
Modulators of intercellular gap junctional communication and their use in the treatment of diabetic eye disease
|
|
GB201800873D0
|
|
Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
|
|
WO2018104558A1
|
|
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104559A1
|
|
Glp-1/glp-2 dual agonists
|
|
AU2017373901A1
|
|
GLP-1/GLP-2 dual agonists
|
|
PE20191083A1
|
|
DUAL ACCYLATED GLP-1 / GLP-2 AGONISTS
|
|
US2018071366A1
|
|
Amylin analogues
|
|
GB201714203D0
|
|
Dosage regimes for the administration of Glucagon-Like Peptide-2(GLP-2)Analogues
|
|
GB201710822D0
|
|
Methods and medical uses relating to the treatment of hypoglycaemia
|
|
GB201709643D0
|
|
Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
|
